Oncology and Hematology

1-16 of 753

• 

  RestartResume

  Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia

  RestartResume

  Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia

  Project Oncology®

  Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia

  Charles Turck, PharmD, BCPS, BCCCP; Douglas A. Tremblay, MD

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Douglas A. Tremblay, MD

• 

  RestartResume

  Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer

  RestartResume

  Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer

  Project Oncology®

  Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer

  Steve Jackson, PharmD; Apar Kishor Ganti, MD

  • 

    

    Steve Jackson, PharmD

  • 

    

    Apar Kishor Ganti, MD

  • 

    

    Thomas Marron, MD, PhD

• 

  RestartResume

  Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice

  RestartResume

  Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice

  CME/CE

  Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice

  Amer Zeidan, MBBS; Ghayas Issa, MD

  0.50 credits

  • 

    

    Amer Zeidan, MBBS

  • 

    

    Ghayas Issa, MD

  0.50 credits

• 

  RestartResume

  Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer

  RestartResume

  Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  CME/CE Virtual Event

  Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure

  Multiple dates available

  0.50 credits

• 

  RestartResume

  Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer

  RestartResume

  Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer

  MinuteCE®

  Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  MinuteCE®

  Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 credit 5 episodes

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 credit 5 episodes

• 

  RestartResume

  Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer

  RestartResume

  Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  RestartResume

  Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer

  RestartResume

  Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  RestartResume

  Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer

  RestartResume

  Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer

  Kathleen N. Moore, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Kathleen N. Moore, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  RestartResume

  Real-World Outcomes with Axatilimab in cGVHD

  RestartResume

  Real-World Outcomes with Axatilimab in cGVHD

  Project Oncology®

  Real-World Outcomes with Axatilimab in cGVHD

  Brian P. McDonough, MD, FAAFP; Hana Safah, MD

  • 

    

    Brian P. McDonough, MD, FAAFP

  • 

    

    Hana Safah, MD

• 

  RestartResume

  Axatilimab’s Impact on cGVHD and Associated BOS

  RestartResume

  Axatilimab’s Impact on cGVHD and Associated BOS

  Project Oncology®

  Axatilimab’s Impact on cGVHD and Associated BOS

  Charles Turck, PharmD, BCPS, BCCCP; Amandeep Salhotra, MD

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Amandeep Salhotra, MD

• 

  RestartResume

  Advanced Urothelial Carcinoma: Optimizing Second-Line Care

  RestartResume

  Advanced Urothelial Carcinoma: Optimizing Second-Line Care

  Project Oncology®

  Advanced Urothelial Carcinoma: Optimizing Second-Line Care

  Guru P. Sonpavde, MD

  • 

    

    Guru P. Sonpavde, MD

• 

  RestartResume

  Current Approaches to Advanced Urothelial Carcinoma

  RestartResume

  Current Approaches to Advanced Urothelial Carcinoma

  Project Oncology®

  Current Approaches to Advanced Urothelial Carcinoma

  Guru P. Sonpavde, MD

  • 

    

    Guru P. Sonpavde, MD

• 

  RestartResume

  The Art of Treatment Sequencing in Advanced Urothelial Carcinoma

  RestartResume

  The Art of Treatment Sequencing in Advanced Urothelial Carcinoma

  Project Oncology®

  The Art of Treatment Sequencing in Advanced Urothelial Carcinoma

  Guru P. Sonpavde, MD

  • 

    

    Guru P. Sonpavde, MD

• 

  RestartResume

  First-Line Treatment Considerations in Advanced Urothelial Carcinoma

  RestartResume

  First-Line Treatment Considerations in Advanced Urothelial Carcinoma

  Project Oncology®

  First-Line Treatment Considerations in Advanced Urothelial Carcinoma

  Guru P. Sonpavde, MD

  • 

    

    Guru P. Sonpavde, MD

• Prev
• 1
• 2
• 3
• …
• 47
• 48
• Next